March 12, 2020
Medicago produces a viable vaccine candidate for COVID-19
The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology Medicago’s platform…
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
March 5, 2020
Amunix nets $73M in Series A financing round
Amunix Pharmaceuticals, a tumor cancer-focused biopharmaceutical company has completed $73 million Series A financing round.
February 25, 2020
Moderna ships mRNA vaccine against coronavirus (mRNA-1273) for Phase 1 study
mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical…
February 25, 2020
Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results in the Lancet Digital Health
First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD…
January 28, 2020
Adverum Biotechnologies opens new HQ in Redwood City, San Francisco
Clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, Adverum Biotechnologies on Tuesday announced the opening of its new corporate headquarters at one of the largest biotechnology research complexes in the San Francisco Bay Area.
December 10, 2019
Merck buys ArQuele for $2.7 billion
Merck said Monday that it iwll, through a subsidiary, initiate a tender offer to acquire all outstanding shares of ArQule for nearly $2.7 billion, or for $20 per share in cash.
December 10, 2019
FDA to fast track Equillium’s itolizumab for lupus nephritis
Equillium got U.S. FDA’s Fast Track designation for itolizumab for the treatment of lupus nephritis, after startign the phase 1 study of itolizumab in patients with lupus and lupus nephritis in September 2019.
December 9, 2019
Inceptua, Onconova Therapeutics in pre-approval access collaboration
Inceptua Medicines Access, a business unit of the Inceptua Group, has announced the collaboration with Onconova Therapeutics to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.
December 9, 2019
Actinium’s phase 3 trial dosimetry results support low dose iomab-B for targeted lymphodepletion prior to adoptive cell therapy
Actinium Pharmaceuticals is advancing the development of low dose Iodine-131 apamistamab, a CD45 targeting antibody radiation-conjugate (ARC), as an alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens like fludarabine/cyclophosphamide (Flu/Cy), which have been implicated in CAR-T toxicities including cytokine release syndrome (CRS) and neurotoxicity.
December 6, 2019
Novartis’ clinical trial of inhaled dual combination QMF149 for patients with asthma, meets primary endpoint
Novartis Phase III Palladium clinical trial has met the primary endpoing, as it showed that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate (IND/MF) in development, was superior to mometasone furoate (MF) at medium and high doses in improving lung function.